Perficient: Drug Development

DECEMBER 19, 2024

A hospital in Seattle integrated universal design principles to support patients with complete blindness. Better Patient Experience: An inclusive environment creates a more welcoming and supportive experience for patients with complete blindness, leading to higher satisfaction.

Hospitals

Broad Institute

JANUARY 6, 2025

Two Broad affiliates also received the award: Paula Hammond, an MIT Institute Professor and vice provost for faculty, and David Walt, Hansjrg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School and a professor of pathology at Brigham and Womens Hospital.

Medical Schools

The Pharma Data

JUNE 26, 2025

Traditionally, CAR T therapy has been confined to large academic or research hospitals due to its complexity. For patients battling aggressive blood cancers and for the health systems that support them, this evolution in treatment protocols could mean quicker access, fewer hospital stays, and ultimately, improved outcomes.

FDA Approval

Drug Target Review

JUNE 30, 2025

He trained at Massachusetts General Hospital and the Harvard School of Public Health. Prior to his industry career, Dr Lepore was a faculty member at the University of Pennsylvania and a practising cardiologist. He holds a degree in biology from the University of Scranton and earned his medical degree from Harvard Medical School.

Disease

Drug Target Review

JULY 15, 2025

For instance, a recent study at Heidelberg University Hospital in Germany demonstrated the patient benefits of automating NGS workflows. 9 Many hospitals and regional medical centres traditionally forced to outsource NGS testing due to limited in-house capabilities and high costs can now implement automated assays locally.

RNA

The Pharma Data

JUNE 23, 2025

This was evaluated using a robust composite endpoint that included all-cause mortality, non-planned PAH-related hospitalization lasting over 24 hours, atrial septostomy (a surgical intervention to reduce right heart pressure), lung transplantation, or progressive clinical deterioration of PAH symptoms.

Trials

Drug Target Review

MAY 21, 2025

With the organisation’s 80-year history serving hospitals and communities, they are now expanding their impact in the CGT space. This makes it a natural partner not only for therapy developers seeking agile, scalable solutions but also for hospitals aiming to deliver complex therapies closer to home.

Therapies

Broad Institute

MAY 21, 2025

The score, called an MM-like score, assesses the severity of disease and risk of progression to active cancer, with higher scores indicating faster progression. These insights wouldn't be possible without access to deeply sequenced whole genomes from a large number of patients and across different disease stages."

DNA

Broad Institute

JUNE 24, 2025

was led by physician-scientists Kiran Musunuru and Rebecca Ahrens-Nicklas at the Children’s Hospital of Philadelphia and U. The team that treated K.J. Some of these treatments, like K.J.’s,

Treatment

Drug Target Review

JUNE 19, 2025

from Georgetown University and completed his General Surgery Residency at Mount Sinai Hospital in New York and a Vascular Surgery Fellowship at Yale University. Dr Bazan holds a B.S. in Molecular Biology from Vanderbilt University, a Howard Hughes Medical Institutes Research Scholar M.D.

Clinical Trials

The Pharma Data

JUNE 15, 2025

Gemelli University Hospital Foundation in Rome, Italy, explained, “Patients suffering from chronic rhinosinusitis with nasal polyps often live with the constant obstruction of their nasal passages, nasal congestion, and a reduced ability to smell — symptoms that profoundly diminish their health-related quality of life.

Treatment

The Pharma Data

JUNE 12, 2025

Fox Chair in Medicine at Massachusetts General Hospital, and Executive Chairman of The IgG4ward! John Stone, MD, MPH , Professor of Medicine at Harvard Medical School, the Edward A.

Disease

The Pharma Data

JUNE 9, 2025

The Urgent Need for RSV Prevention in Infants Respiratory syncytial virus is the leading cause of infant hospitalizations in the United States, and it is known to trigger severe respiratory illnesses such as bronchiolitis and pneumonia in young children. RSV disease is the leading cause of infant hospitalization in the U.S.

FDA Approval

Drug Target Review

DECEMBER 16, 2024

This field allowed me the privilege of tending to children in the hospital and building long-term relationships with them and their families. Along the way, I realised that my passion was to take care of children who were sick, which led me to choose a career in pediatrics and subsequently pediatric hematology-oncology.

Medical Schools

The Pharma Data

JUNE 18, 2025

He later served on the faculty of Harvard Medical School and Brigham & Women’s Hospital in Boston, contributing to both patient care and academic medicine before transitioning to the biopharmaceutical industry. Garg was selected as a fellow in the prestigious Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University.

RNA

The Pharma Data

JULY 2, 2025

The regimen includes mandatory hospitalization for 24 hours following each of the first two step-up doses, a precaution to manage cytokine release syndrome (CRS) and other adverse reactions. The dosing strategy includes: Step-Up Dosing: Designed to reduce the risk of CRS, requiring hospitalization after each of the first two step-up doses.

FDA

The Pharma Data

JUNE 15, 2025

Infections were documented in 18 patients (58% of the study population), with 5 cases (16%) classified as serious; none resulted in a grade 5 event (death related to the study treatment).

Therapies

Drug Target Review

MAY 23, 2025

Currently, treatments involving bispecific antibodies require patients to remain in the hospital for extended periods to monitor for side effects, especially CRS. One of the most promising implications of POLB 001 lies in its potential to enable outpatient cancer immunotherapy.

Immune Response

The Pharma Data

JUNE 27, 2025

Jude Children’s Research Hospital. “These emerging data indicate that additional gains in function might be possible even in those with established disease who have been on therapy for years,” said Dr. Richard Finkel, director of the Center for Experimental Neurotherapeutics at St.

Treatment

LifeSciVC

JULY 8, 2025

Before biotech, I was a practicing anesthesiologist, then a hospital administrator. I thought of the experience of running operating rooms overnight in smaller regional hospitals, what Hayes might call austere environments. And something about it stuck. That background shaped how I heard the keynote.

Hospitals

Broad Institute

MAY 27, 2025

Mandana Arbab, a postdoctoral researcher in Lius lab when the study began who now holds the Lodish Family chair as an assistant professor at Boston Childrens Hospital, and Zaneta Matuszek, then a graduate student, are co-first authors on the study.

DNA

Drug Target Review

JULY 10, 2025

Prior to Flatiron, Josh was at MIT studying computer science and working with researchers at Massachusetts General Hospital to use ML and NLP to predict patient response to cardiac resynchronisation therapy.

Metabolic Stability

Conversations in Drug Development Trends

OCTOBER 14, 2024

For patients with autoimmune diseases, these new therapies mean fewer hospitalizations, less pain, and more days where they can live a normal life without debilitating symptoms. How Our Global Network and Innovation Impacts Patients’ Lives The importance of these innovations cannot be overstated.

Research

The Pharma Data

JUNE 11, 2025

Dr. Isabelle Peene, rheumatologist at Ghent University Hospital and study investigator, highlighted the implications: “Targeting FcRn and reducing IgG autoantibodies appear to have meaningful clinical impact in Sjogren’s disease.

Disease

Broad Institute

MAY 19, 2025

Chan School of Public Health, including Neale; Mark Daly, institute member and co-director of Broads Program in Medical and Population Genetics; Javaras; and Archana Basu , a clinical psychologist at Massachusetts General Hospital and an instructor at Harvard Medical School.

DNA

Broad Institute

NOVEMBER 25, 2024

Our Partners Broad Institute Rare Genomes Project Boston Children’s Hospital CZI Rare as One Network To access a curated list of gene and cell therapy trials, please visit the ASGCT Clinical Trials Finder. Please speak with your healthcare provider before enrolling in a clinical trial.

Clinical Trials

The Pharma Data

JUNE 26, 2025

These dual decisions mark a significant advancement in efforts to combat RSV-related lower respiratory tract disease (LRTD) in infants—a leading cause of hospitalization in this vulnerable age group. pediatric population. often peaking between October and March. Dr. Richard M. As the U.S.

Vaccine

The Pharma Data

JUNE 11, 2025

Dr. Ioannis Parodis, MD, PhD, Associate Professor of Rheumatology at Karolinska University Hospital in Sweden, emphasized the importance of these findings in addressing fatigue, a hallmark symptom in lupus that often remains difficult to manage.

Disease

The Pharma Data

JULY 3, 2025

The results, recently published in the International Journal of Molecular Sciences , come from a collaborative effort between researchers at Erlangen University Hospital and Berlin-based biotech firm AudioCure. Tinnitus—commonly experienced as a persistent ringing or buzzing in the ears—affects an estimated 10–15% of the adult population.

Clinical Trials

The Pharma Data

JUNE 9, 2025

RSV is the leading cause of lower respiratory tract disease and a top reason for hospitalization among infants. Importantly, most RSV-related hospitalizations occur in healthy, full-term infants who previously showed no signs of underlying health conditions.

Virus

ACTO

JULY 23, 2025

By integrating unique HCP data and insights from Veeva Vault CRM—such as prescribing behavior, hospital affiliations, patient volume estimates, and speaker program participation— My HCP will allow field users to practice with realistic digital twins of their actual customers.

Science

Drug Target Review

APRIL 14, 2025

By preventing infections before they occur, these drugs reduce the need for hospital treatments, including the costly intensive care unit (ICU) care that can burden healthcare systems. As Finrow reflects, “If we can keep people out of hospital ICUs, thats even more value delivered.

Therapies

Broad Institute

NOVEMBER 21, 2024

In a study published in Nature Cancer , researchers at the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Massachusetts General Hospital investigated the evolution of these tumors, many of which are known to be initiated by mutations in an enzyme known as IDH.

Research

PLOS: DNA Science

APRIL 17, 2025

When their pediatrician saw the child walking on her tiptoes and unable to manage stairs, the next step was Children’s Hospital of Philadelphia. Developmental delays accrued, therapists descended, tests began. There, MRI revealed the distinctive white matter brain changes of MLD.

Therapies

The Pharma Data

JULY 3, 2025

. “Pancreatic cancer often causes severe, chronic pain that drastically diminishes patients’ quality of life,” said Dr. Teresa Macalura, Medical Oncologist at Vall d’Hebron University Hospital and Head of the Gastrointestinal and Endocrine Tumor Group at the Vall d’Hebron Oncology Institute (VHIO).

Therapies

The Pharma Data

JUNE 6, 2025

This number underscores the urgency of expanding access to effective, tolerable, and convenient treatment options.

Treatment

Conversations in Drug Development Trends

JULY 3, 2025

For instance, the regulations required patients to remain in close proximity to the healthcare facility for a full four weeks, which became difficult if the patient needed to transfer hospitals or lived far away from certified centers.

Therapies